AbbVie’s Humira (adalimumab) and Merck, Sharp, and Dohme’s (MSD) Remicade (infliximab) are mega-blockbusters – but Humira is nearing the end of its patent life in the EU, and Remicade is no ...
Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback